文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌立体定向体部放疗晚期毒性受试者工作特征曲线与剂量体积分析

Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer.
PubMed 文献 · Pract Radiat Oncol · 2016-07-17

采用受试者工作特征曲线方法确定晚期泌尿生殖毒性剂量阈值,发现晚期2级及以上毒性与处方等剂量线及正常化体积异质性≥46 Gy相关,建议控制前列腺V46 Gy<36.7%、V48 Gy<21%、V50 Gy<9.5%以使晚期2级及以上泌尿生殖毒性≤20%。

要点

  • 晚期2级及以上泌尿生殖毒性与处方等剂量线及正常化体积异质性≥46 Gy相关。
  • 前列腺V46 Gy<36.7%、V48 Gy<21%、V50 Gy<9.5%可控制晚期2级及以上泌尿生殖毒性≤20%。
  • 提高处方等剂量线(>69%)可能有助于实现上述剂量体积阈值。

核心结论

  • 前列腺内剂量异质性应予以控制,潜在阈值包括正常化前列腺体积V46 Gy<36.7%、V48 Gy<21%、V50 Gy<9.5%,以保持4次分割方案下晚期2级及以上泌尿生殖毒性≤20%。
  • 通过提高处方等剂量线(>69%)可能有助于实现上述剂量体积阈值。

研究设计与样本

  • 采用基于逻辑回归模型的受试者工作特征曲线分析确定晚期泌尿生殖毒性的最佳剂量学参数。

主要发现

  • 治疗时中位年龄69岁,中位前列腺体积46.2 mL,中位处方等剂量线67%(四分位距65-70),中位临床随访35.49个月。
  • 晚期1级、2级、3级泌尿生殖毒性发生率分别为21.8%、19.2%、2.6%。
  • 受试者工作特征曲线方法成功得出前列腺和尿道的剂量体积推荐阈值,包括正常化前列腺体积46至50 Gy相关参数,例如V46 Gy为36.7%(敏感度71%,特异度61%,曲线下面积0.67),对应晚期2级及以上泌尿生殖毒性概率21%。

关键数值与推荐

  • 正常化前列腺体积V46 Gy<36.7%、V48 Gy<21%、V50 Gy<9.5%可作为控制晚期2级及以上泌尿生殖毒性≤20%的潜在阈值。
  • 处方等剂量线>69%可能有助于实现上述剂量体积阈值。

临床怎么用

  • 在前列腺癌4次分割立体定向体部放疗计划中,可参考V46 Gy<36.7%、V48 Gy<21%、V50 Gy<9.5%的剂量体积阈值以控制晚期2级及以上泌尿生殖毒性。
  • 可考虑将处方等剂量线提高至>69%以协助满足上述剂量体积约束。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to evaluate a receiver operating characteristic (ROC) curve method to determine dose thresholds with late genitourinary (GU) toxicity after stereotactic body radiation therapy for prostate cancer. METHODS AND MATERIALS: Seventy-eight patients diagnosed with low- to intermediate-risk prostate cancer and treated with stereotactic body radiation therapy alone were reviewed retrospectively. All patients received a total dose of 38 Gy in 4 fractions with a planning target volume expansion of 2 mm. GU toxicity was documented according to the Common Terminology Criteria for Adverse Events, version 4. ROC analysis applied on a logistic regression model was used to determine optimal dosimetric parameters for GU toxicity. RESULTS: The median age at treatment was 69 years with a median prostate volume of 46.2 mL. The median prescription isodose line was 67% (interquartile range, 65, 70). The median clinical follow-up was 35.49 months. Late grade 1, 2, and 3 GU toxicity occurred in 21.8%, 19.2%, and 2.6% of cases, respectively. Late grade 2+ GU toxicity was associated with prescription to isodose line (P = .009) and normalized volumes for heterogeneity ≥46 Gy. The ROC method successfully produced thresholds for dose-volume recommendations for both prostate and urethra, including normalized prostate volumes from 46 to 50 Gy, such as volume of target tissue receiving 46% of the prescribed dose (V46) Gy of 36.7% (sensitivity, 71%; specificity, 61%; area under the curve, 0.67) with an associated probability of late GU grade 2+ toxicity of 21%. CONCLUSIONS: Intraprostatic heterogeneity should be controlled with potential thresholds at V46 Gy <36.7%, V48 Gy <21%, and V50 Gy <9.5% of the normalized prostate volume to keep late grade 2+ GU toxicity ≤20% with 4-fraction schemes. This may be facilitated with a higher prescription isodose line (>69%).

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang L, Johnson J, Gottschalk AR, et al. Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2016. PMID: 28274401. doi:10.1016/j.prro.2016.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。